Elsevier,
European Journal of Radiology, Volume 165, August 2023
This review is to provide a comprehensive overview of recent developments in deep learning methodologies applied to brain MRI images for the classification of various stages of Alzheimer's disease, with a particular emphasis on early diagnosis. Furthermore, this review underscores the limitations of current research, discussing potential challenges and future research directions in this dynamic field.
Elsevier,
The Lancet Microbe, Volume 4, August 2023
This study supports SDGs 3 and 6 by showing that areas with better access to drinking water and sanitation had a lower abundance of antibiotic resistance genes, suggesting that increasing access to water and sanitation could effectively reduce the spread of antibiotic resistance in low-income and middle-income countries
Elsevier,
eBioMedicine, Volume 94, August 2023
This Article supports Sustainable Development Goal 3 by advancing our understanding of the possible role of active immunotherapy against amyloid-β in individuals with mild Alzheimer's disease; the findings of this phase 2a study support the continued clinical development of UB-311 as an active immunotherapy for Alzheimer's disease.
Elsevier,
eBioMedicine, Volume 94, August 2023
This Article supports Sustainable Development Goal 3 by identifying an independent relationship between anxiety and subsequent cognitive progression in older people without dementia; these findings suggest that treating anxiety and targeting mitochondrial dysfunction may be effective in preventing dementia.
Elsevier,
The Lancet Healthy Longevity, Volume 4, August 2023
This Article supports Sustainable Development Goal 3 by showing that although there was an increase in prescribing of antipsychotics to people with dementia during the COVID-19 pandemic, this increase was not responsible for the large increase in all-cause and stroke mortality in this population.
Elsevier,
The Lancet Regional Health - Southeast Asia, Volume 15, August 2023
Daily oral pre-exposure prophylaxis (PrEP) is effective in preventing HIV infection, MSM and TGW who exchange sex can have high PrEP uptake, persistence and adherence, and low HIV incidence when offered in supportive community-based settings.
Elsevier, The Lancet Regional Health - Western Pacific, Volume 37, August 2023
Background: Towards hepatitis C elimination among people who inject drugs (PWID), we assessed the effectiveness of a strategy consisting of a community-based respondent-driven sampling (RDS) as wide screening, a simplified and integrated hospital-based care, and prevention of reinfection supported by community-based organisations (CBO), in Hai Phong, Vietnam. Methods: Adults who injected heroin were enrolled in a RDS survey implemented in two CBO premises. Rapid HIV and HCV tests were done on site, and blood was taken for HCV RNA testing.
Elsevier,
The Lancet Regional Health - Europe, Volume 31, August 2023
This Comment supports SDGs 3 and 13 by highlighting the negative health impacts of climate change around the world and in Europe, and noting that populations most impacted by climate change tend to be the least responsible for contributing to it. The authors note that, like in the Global South, the most disadvantaged communities in Europe bear disproportionate burdens of negative health impacts of climate change, but that addressing this inequity is not currently an explicit goal of EU policies.
Elsevier,
The Lancet HIV, Volume 10, August 2023
This Article supports SDG 3 by showing that men who have sex with men (MSM) in Africa remain highly vulnerable to HIV acquisition and HIV-related mortality and morbidity, undermining the Global AIDS Strategy to end AIDS; realising the UNAIDS 95-95-95 targets and reducing disparities in HIV incidence requires urgent efforts to strengthen community-led prevention efforts.
Elsevier,
The Lancet Global Health, Volume 11, August 2023
This Article supports SDG 3 by showing that short-course tuberculosis preventive treatment is likely to be cost-effective (compared with no tuberculosis preventive treatment) for adult contacts in 15 countries and people living with HIV/AIDS in seven countries, even under conservative cost-effectiveness thresholds.
